ERS Genomics and IRBM sign license agreement for CRISPR/Cas9
Betsy Goodfellow | May 20, 2024 | News story | Research and Development |Â Â CRISPR/Cas9, ERS Genomics, IRBM, License Agreement, PharmacyÂ
ERS Genomics and IRBM have announced that they have entered into a non-exclusive CRISPR/Cas9 license agreement, granting IRBM access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Financial details of the agreement have not yet been disclosed.
IRBM is a drug discovery CRO with a focus from target validation to finding preclinical candidates, spanning indications such as oncology, neurology and infectious diseases. Meanwhile, ERS Genomics often provides licensing to CRISPR/Cas9 technology for other companies, covering CRISPR/Cas9 use in all cells, including eukaryotic and prokaryotic cells.
John E Milad, chief executive officer at ERS Genomics, commented: “We are committed to supporting cutting-edge research and expanding the horizons of medical innovation by providing companies such as IRBM with the ability to take advantage of CRISPR/Cas9 technology. We look forward to seeing the innovative ways in which our gene editing technology will be utilised in various stages of drug discovery, providing candidates for a wide range of therapeutic areas.”
Carlo Toniatti MD PhD, chief scientific officer at IRBM, added: “We are committed to delivering high quality drugs by leveraging our broad range of expertise and capabilities across the entire preclinical drug discovery continuum. With the integration of CRISPR/Cas9 gene editing technology we are increasing our capability to identify and validate potential drug targets, to generate more predictive pre-clinical models and to elucidate the mechanisms of action of novel therapeutics.”
Betsy Goodfellow
Related Content
GSK and CureVac to restructure collaboration into licensing agreement
GSK and CureVac have announced that they have restructured their existing collaboration into a license …
Provectus Biopharmaceuticals announces license agreement with University of Miami
Provectus Biopharmaceuticals has announced that it has entered into an exclusive worldwide license agreement with …
Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement
Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a …
